Clinical Implications of Ivabradine in the Contemporary Era

Teruhiko Imamura1

  • 1The Second Department of Internal Medicine, University of Toyama, Toyama 930-8555, Japan.

PubMed

Insights

Ivabradine, an If ion channel inhibitor, effectively reduces heart rate in heart failure patients. Echocardiography-guided therapy optimizes its use, improving cardiac remodeling and patient outcomes.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biomedical Engineering

Background:

  • Ivabradine inhibits the If ion channel, lowering heart rate while maintaining hemodynamic stability.
  • Current indication: heart failure with reduced ejection fraction refractory to beta-blockers.
  • Aggressive up-titration of ivabradine optimizes heart rate control and facilitates beta-blocker titration.

Purpose of the Study:

  • To introduce and explain the novel overlap theory for optimizing ivabradine therapy.
  • To explore the application of echocardiography-guided ivabradine therapy for improved patient outcomes.
  • To discuss the potential expansion of ivabradine's clinical indications.

Main Methods:

  • Utilizing trans-mitral Doppler echocardiography to assess E-wave and A-wave overlap.
  • Implementing echocardiography-guided ivabradine therapy to minimize E-wave and A-wave overlap.
  • Reviewing existing literature on ivabradine's efficacy and potential new applications.

Main Results:

  • Optimal heart rate, identified by minimal E-wave and A-wave overlap, confers substantial benefits.
  • Echocardiography-guided ivabradine therapy promotes superior cardiac reverse remodeling.
  • This approach leads to more favorable clinical outcomes compared to standard care.

Conclusions:

  • Echocardiography-guided ivabradine therapy, based on the overlap theory, enhances cardiac reverse remodeling and clinical outcomes.
  • Ivabradine may not benefit patients with heart failure with preserved ejection fraction, acute heart failure, sepsis, or stable angina.
  • Further investigation is needed for ivabradine's applicability in atrial fibrillation.

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
996
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
832
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
744
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
448
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
588